Calcium Acetate
drugOn this page
Also known as Acetic acidcalcium saltAcetic acid, calcium salt (2:1)Calcarea aceticaCalcium acetate anhydrousCalcium acetate component of procalamineanhydrousE-263E263EliphosEveroseFEMA NO. 2228INS NO.263INS-263PhosexPhosloPhoslo gelcapsPhoslyraRenacet
Summary
Calcium Acetate (CHEMBL1200800) is an approved small-molecule chelator (ATC V03AE07); indicated across 5 conditions including hyperphosphatemia and chronic kidney disease.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: V03AE07
- Indications: 5 conditions
- Clinical trials: 10
- Chemistry: 158.17 Da · C4H6CaO4
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1200800 |
| Name | Calcium Acetate |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | yes |
| PubChem CID | 6116 |
| ChEBI | CHEBI:3310 |
| ATC | V03AE07 |
| Molecular formula | C4H6CaO4 |
| Molecular weight | 158.17 |
| InChIKey | VSGNNIFQASZAOI-UHFFFAOYSA-L |
SMILES: CC(=O)[O-].CC(=O)[O-].[Ca+2]
IUPAC name: calcium diacetate
ChEBI definition: The calcium salt of acetic acid. It is used, commonly as a hydrate, to treat hyperphosphataemia (excess phosphate in the blood) in patients with kidney disease: the calcium ion combines with dietary phosphate to form (insoluble) calcium phosphate, which is excreted in the faeces.
Pharmacological roles (ChEBI): chelator.
Also known as: Acetic acid, calcium salt, Acetic acid, calcium salt (2:1), Calcarea acetica, Calcium acetate, Calcium acetate anhydrous, Calcium acetate component of procalamine, anhydrous, E-263, E263, Eliphos, Everose
Patent coverage: 24,840 distinct patent families (64,576 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
5 indications (4 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| hyperphosphatemia | 4 | MONDO:0000328 | HP:0002905 |
| chronic kidney disease | 4 | MONDO:0005300 | EFO:0003884 |
| kidney failure | 4 | MONDO:0001106 | EFO:1002048 |
2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 10.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE4 | 3 |
| Not specified | 3 |
| PHASE3 | 1 |
| PHASE2 | 1 |
| EARLY_PHASE1 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00211939 | PHASE4 | COMPLETED | CARE-2 (Calcium Acetate [PhosLo®]/Sevelamer[Renagel®] Evaluation Study 2) for Heart Calcification in Dialysis Patients |
| NCT01135615 | PHASE4 | COMPLETED | Sevelamer, FGF-23 and Endothelial Dysfunction in Chronic Kidney Disease (CKD) |
| NCT01277497 | PHASE4 | TERMINATED | Effect of Phosphate Binders on Markers of Vascular Health in Chronic Kidney Disease Stages 3 and 4 |
| NCT00211978 | PHASE3 | COMPLETED | EPIC(Effect of PhosLo on Phosphorus Levels in Chronic Kidney Disease) |
| NCT05424263 | PHASE2 | UNKNOWN | Acetate and Age-associated Arterial Dysfunction |
| NCT04299633 | PHASE1 | COMPLETED | Study in Healthy Adult Subjects to Assess the Effect of Phosphate Binders on the Pharmacokinetics of a Single Dose of Vadadustat |
| NCT01991574 | EARLY_PHASE1 | COMPLETED | Effect of the Consumption of Ferric Hydroxide Adipate on Urinary Phosphorus Excretion. |
| NCT00018135 | Not specified | COMPLETED | Parathyroid Hormone Levels in Relation to the Phosphorus Content of Meals |
| NCT00364000 | Not specified | WITHDRAWN | Arterial Stiffness and Calcifications in Haemodialysis Patients on Sevelamer or Calcium Acetate |
| NCT00785629 | Not specified | COMPLETED | A Double Blind Randomized Placebo Trial of Maintenance of Normal Serum Phosphorus in CKD |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: hyperphosphatemia, chronic kidney disease, kidney failure